Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 3/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.47 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.45 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.45 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | FNTA | P49354 | 7/20 | 0.39 |
| ▸ | FNTB | P49356 | 7/20 | 0.39 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8528253 | 1.00 | MME (0.52) | MMEPTGS1SLC7A11PDCD1LG2CD274 | |
| SCHEMBL11324778 | 1.00 | MME (0.52) | MMEPTGS1SLC7A11PDCD1LG2CD274 | |
| SCHEMBL11324786 | 1.00 | MME (0.52) | MMEPTGS1SLC7A11PDCD1LG2CD274 | |
| SCHEMBL29351638 | 0.94 | MME (0.48) | MMEPTGS1SLC7A11PDCD1LG2CD274 | |
| SCHEMBL29793176 | 0.90 | MME (0.46) | MMEPTGS1SLC7A11PDCD1LG2CD274 | |
| SCHEMBL30272523 | 0.88 | OPRM1 (0.46) | MMEPDCD1LG2CD274ACEFNTA | |
| SCHEMBL30603413 | 0.88 | OPRM1 (0.46) | MMEPDCD1LG2CD274ACEFNTA | |
| SCHEMBL30811198 | 0.88 | MMP1 (0.44) | MMEPTGS1SLC7A11PDCD1LG2CD274 | |
| SCHEMBL6791478 | 0.87 | MME (0.51) | MMEPTGS1SLC7A11ACEFNTA | |
| SCHEMBL6791475 | 0.87 | MME (0.51) | MMEPTGS1SLC7A11ACEFNTA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4448545-B1 | MANUFACTURING PROCESS FOR THE PRODUCTION OF LINACLOTIDE | CHEMI SPA (IT) | 2025-08-20 | — | — | EP | claimed |
| US-20260117070-A1 | NEAR-INFRARED FLUORESCENT HEPTAMETHINE DYE CONJUGATES WITH FAVORABLE BLEACHING PROPERTIES | HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM GESUNDHEIT & UMWELT GMBH (DE) | 2026-04-30 | — | — | US | disclosed |
| US-12570729-B2 | Antibody fragment based antifungal conjugate selectively targeting candida | ABGENICS LIFESCIENCES PRIVATE LIMITED (IN) | 2026-03-10 | — | — | US | disclosed |
| EP-4684030-A2 | METHOD OF DEPROTECTING AT LEAST ONE D-AMINO ACID AND/OR D-AMINO ACID DERIVATIVE PROTECTED FUNCTIONAL GROUP | Martin-Luther-Universität Halle-Wittenberg (DE) | 2026-01-28 | — | — | EP | disclosed |
| EP-4610269-A1 | UROKINASE PLASMINOGEN ACTIVATOR SURFACE RECEPTOR (UPAR) LIGANDS FOR DIAGNOSTIC OR THERAPEUTIC USE | 3B Pharmaceuticals GmbH (DE) | 2025-09-03 | — | — | EP | disclosed |
| CN-119015278-B | Cymosine-polypeptide coupled compound, and preparation method and application thereof | 广州医科大学 | 2025-03-14 | — | — | CN | disclosed |
| US-20250066418-A1 | CYSTEINE PEPTIDE-ENABLED ANTIBODIES | CITY OF HOPE | 2025-02-27 | — | — | US | disclosed |
| CN-119015278-A | Novel use of cytisine, cytisine-polypeptide coupled compound, preparation method and use thereof | 广州医科大学 | 2024-11-26 | — | — | CN | disclosed |
| WO-2024227957-A2 | METHOD OF DEPROTECTING AT LEAST ONE D-AMINO ACID AND/OR D-AMINO ACID DERIVATIVE PROTECTED FUNCTIONAL GROUP | Martin-Luther-Universität Halle-Wittenberg (DE) | 2024-11-07 | — | — | WO | disclosed |
| US-20240092878-A1 | AN ANTIBODY FRAGMENT BASED ANTIFUNGAL CONJUGATE SELECTIVELY TARGETING CANDIDA | ABGENICS LIFESCIENCES PRIVATE LIMITED (IN) | 2024-03-21 | — | — | US | disclosed |
| CN-117701633-A | Method for regulating high mannose sugar type antibody in CHO cell, CHO cell and application thereof | 上海凯莱英生物技术有限公司 | 2024-03-15 | — | — | CN | disclosed |
| JP-2024015361-A | STABLE SOLID FORMULATIONS OF GC-C RECEPTOR AGONIST POLYPEPTIDE SUITABLE FOR ORAL ADMINISTRATION | アイアンウッド ファーマシューティカルズ インコーポレイテッド | 2024-02-01 | — | — | JP | disclosed |
| CN-116716324-A | Alkane degradation gene, protein and application thereof | 山东省科学院生态研究所(山东省科学院中日友好生物技术研究中心) | 2023-09-08 | — | — | CN | disclosed |
| CN-116287039-A | Biological method for synthesizing spermidine by cell-free catalysis | 南京工业大学 | 2023-06-23 | — | — | CN | disclosed |
| US-20230128688-A1 | DIRECTED CONJUGATION TECHNOLOGIES | KLEO PHARMACEUTICALS, INC. | 2023-04-27 | — | — | US | disclosed |
| CN-113429453-B | CTV tripeptide and application thereof | 江西农业大学 | 2023-04-07 | — | — | CN | disclosed |
| CN-114478789-A | anti-PD-L1 and OX40 bispecific antibodies and uses thereof | 安徽安科生物工程（集团）股份有限公司 | 2022-05-13 | — | — | CN | disclosed |
| CN-108040482-B | Composition for colon cleansing and treatment of gastrointestinal disorders | 硬木药品公司 | 2022-03-29 | — | — | CN | disclosed |
| EP-0885899-A1 | Method for obtaining peptide fragments by use of fluorinated organic acids | SEIKO INSTRUMENTS INC. (JP) | 1998-12-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570729-B2 | Antibody fragment based antifungal conjugate selectively targeting candida | SERPINH1, HM13, NGLY1 | MME 50/4885PTGS1 4316/4885SLC7A11 1771/4885 |
| US-20230128688-A1 | DIRECTED CONJUGATION TECHNOLOGIES | CD2BP2, CD2, CD47 | MME 653/4885PTGS1 4806/4885SLC7A11 4036/4885 |
| US-20250066418-A1 | CYSTEINE PEPTIDE-ENABLED ANTIBODIES | LNPEP, CSTB, PTMS | MME 495/4885PTGS1 3581/4885SLC7A11 18/4885 |
| US-20260117070-A1 | NEAR-INFRARED FLUORESCENT HEPTAMETHINE DYE CONJUGATES WITH FAVORABLE BLEACHING PROPERTIES | CBR1, CBR3, NR2E3 | MME 2489/4885PTGS1 2677/4885SLC7A11 1908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.